At a $1,073M market cap with no P/E or Forward P/E, this is a pre-profit biotechnology name priced purely on future optionality rather than earnings power. EPS of -3.9 and negative operating margin of -15.10% confirm the absence of operating leverage, while ROIC at -15.20% signals capital destruction rather than compounding. The Altman Z-Score of 1.8 places the company in financial distress territory, meaning solvency risk cannot be ignored despite a strong current ratio of 11.3. With no forward earnings multiple to anchor valuation and a Price/Sales of 14.1, the market is still assigning premium growth expectations to a business that has yet to prove economic viability—this is speculative capital, not discounted cash flow investing.